{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:13:16Z","timestamp":1778803996368,"version":"3.51.4"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Female Clinician Scientist program of Ruhr-Univeristy Bochum, German, Grant number K147-21"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1038\/s41375-022-01763-2","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T12:04:22Z","timestamp":1669377862000},"page":"248-249","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Optical Genome Mapping in MDS and AML as tool for structural variant profiling\u2014comment and data update on Yang et al.: \u201cHigh-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance\u201d"],"prefix":"10.1038","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4175-5683","authenticated-orcid":false,"given":"Deepak B.","family":"Vangala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Nilius-Eliliwi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3858-9872","authenticated-orcid":false,"given":"Wanda M.","family":"Gerding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2744-5491","authenticated-orcid":false,"given":"Roland","family":"Schroers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huu Phuc","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"1763_CR1","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1038\/s41375-022-01652-8","volume":"36","author":"H Yang","year":"2022","unstructured":"Yang H, Garcia-Manero G, Sasaki K, Montalban-Bravo G, Tang Z, Wei Y, et al. High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance. Leukemia. 2022;36:2306\u201316.","journal-title":"Leukemia"},{"key":"1763_CR2","first-page":"924","volume":"384","author":"WM Gerding","year":"2022","unstructured":"Gerding WM, Tembrink M, Nilius-Eliliwi V, Mika T, Dimopoulos F, Ladigan-Badura S, et al. Optical genome mapping reveals additional prognostic information compared to conventional cytogenetics in AML\/MDS patients. Int J Cancer. 2022;384:924\u201335.","journal-title":"Int J Cancer"},{"key":"1763_CR3","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/ajh.26503","volume":"97","author":"DA Arber","year":"2022","unstructured":"Arber DA, Hasserjian RP, Orazi A, Mathews V, Roberts AW, Schiffer CA, et al. Classification of myeloid neoplasms\/acute leukemia: global perspectives and the international consensus classification approach. Am J Hematol. 2022;97:514\u20138.","journal-title":"Am J Hematol"},{"key":"1763_CR4","unstructured":"Bionano Genomics. Bionano Solve Theory of Operation: Structural Variant Calling. 2021."},{"key":"1763_CR5","doi-asserted-by":"publisher","first-page":"959243","DOI":"10.3389\/fonc.2022.959243","volume":"12","author":"V Nilius-Eliliwi","year":"2022","unstructured":"Nilius-Eliliwi V, Tembrink M, Gerding WM, Lubieniecki KP, Lubieniecka JM, Kankel S, et al. Broad genomic workup including optical genome mapping uncovers a DDX3X: MLLT10 gene fusion in acute myeloid leukemia. Front Oncol. 2022;12:959243.","journal-title":"Front Oncol"},{"key":"1763_CR6","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.ajhg.2021.06.001","volume":"108","author":"K Neveling","year":"2021","unstructured":"Neveling K, Mantere T, Vermeulen S, Oorsprong M, van Beek R, Kater-Baats E, et al. Next-generation cytogenetics: Comprehensive assessment of 52 hematological malignancy genomes by optical genome mapping. Am J Hum Genet. 2021;108:1423\u201335.","journal-title":"Am J Hum Genet"},{"key":"1763_CR7","doi-asserted-by":"publisher","unstructured":"L\u00fchmann JL, Stelter M, Wolter M, Kater J, Lentes J, Bergmann AK, et al. The clinical utility of optical genome mapping for the assessment of genomic aberrations in acute lymphoblastic leukemia. Cancers. 2021;13. https:\/\/doi.org\/10.3390\/cancers13174388.","DOI":"10.3390\/cancers13174388"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01763-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01763-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T11:12:10Z","timestamp":1674817930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-022-01763-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":7,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1763"],"URL":"https:\/\/doi.org\/10.1038\/s41375-022-01763-2","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,24]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DBV received speaker\u2019s honoraria from Roche, BMS, Pfizer, and Falk foundation, consultant\u2019s honoraria from Pfizer, Bristol Myers Squibb, and Gilead and travel support and congress registration fees from Gilead, Celgene, and Abbvie. VN-E received travel support and congress registration fees from Jazz Pharmaceuticals. The other authors do not report any conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}